2009-11-03 21:19:02 -

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Robert Perez, EVP and COO, will present on Wednesday, November 18, 2009 at 1:45 p.m. Eastern Time at the Lazard Capital Markets 6 th Annual Healthcare Conference at the St Regis Hotel in New York City. This presentation will include discussion of the company’s business activities, financial outlook, and current news.

A live webcast

of the presentation will be accessible through Cubist’s website at www.cubist.com : in the Investor Relations Conference Calendar section. The webcast will be available on Cubist’s website for a period of 30 days after the presentation.



About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.

In the U.S., Cubist markets CUBICIN ® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist began promoting MERREM ® I.V. (meropenem for injection) in the United States. MERREM is an established broad spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials — CONSERV™-1 and CONSERV™-2 — for the reduction of blood loss during cardiac surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam’s RNA-interference technology. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist’s web site at www.cubist.com : .

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.

AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies.

Cubist Pharmaceuticals, Inc.Eileen C. McIntyre, 781-860-8533Senior
Director, Corporate Communications eileen.mcintyre@cubist.com : mailto:eileen.mcintyre@cubist.com orWeber

ShandwickTara Murphy, 617-520-7045 tara.murphy@webershandwick.com : mailto:tara.murphy@webershandwick.com